Vifor Boosts US Nephrology Prospects With Janssen Pact

Vifor: Selling Invokana In DKD Could Aid Veltassa’s US sales

04 Nov 2019

• By Sten Stovall

Vifor has boosted its US nephrology prospects with a pact with Janssen to jointly market Invokana in diabetic kidney disease.

Vifor Pharma Group said its US commercial presence has been enhanced through a pact with J&J to market Janssen’s SGLT2 inhibitor Invokana (canagliflozin) in its new indication as a treatment for diabetic kidney disease (DKD), as it will complement the Swiss group’s existing operations there.

Invokana had already been available in the US to reduce the risk of major cardiovascular events and improve glycemic control...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

18 Aug 2025

• By Ian Haydock

In this week's episode: a look at the likely top drugs in 2030; Lilly CEO advocates US/Europe pricing rebalance; Insmed sees $5bn-plus market for Brinsupri; royalty deals go mainstream; Phase III win sets stage for Epkinly label expansion.

Finance Watch: Did Mid-Summer Usher In A Mega-Round Comeback?

15 Aug 2025

• By Mandy Jackson

Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.

Tonix Ready To Revive Fibromyalgia Market With Tonyma

15 Aug 2025

• By Joseph Haas

The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.